Summary
Ofloxacin has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Glaucoma would be drug repurposing rather than first-in-human development. This does not mean it is approved for Glaucoma. ClinicalTrials.gov lists 4 registered trials linking Ofloxacin to Glaucoma: 1 is currently recruiting; 3 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT04200651). The largest enrolment is 4000 participants (NCT03631108). Registration activity spans 2018 to 2020. The literature layer holds 2 publications for this pair: 1 Cochrane review and 1 clinical trial publication. Publication years run from 1999 to 2025. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Glaucoma ranks 339 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Progressive optic nerve damage without treatment; average visual field loss 0.5-1.0 dB/year; blindness in 10-20% without treatment; no spontaneous recovery of lost vision.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 38.0 (trials 11.0, literature 7.0, tier 15, approved bonus 5.0) |
| Registered trials | 4 total: 1 recruiting, 0 active / not yet recruiting, 0 completed, 3 other |
| Linked publications | 2 (1 Cochrane review, 1 clinical trial publication) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
| Linked via biomarker / target | ABCA1 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT04200651 | Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery 2020 | terminated | Phase 4 | 25 |
| NCT03933631 | Pilocarpine Use After Kahook Goniotomy 2019 | recruiting | Phase 3 | 142 |
| NCT04005079 | Pilocarpine After Combined Cataract/Trabectome Surgery 2019 | withdrawn | Phase 3 | — |
| NCT03631108 | Feasibility Study and Preliminary Application Study on Iris OCTA 2018 | status unknown | Not applicable | 4,000 |
Published literature
- Cochrane review Topical antibiotics for treating bacterial keratitis: a network meta-analysisSong A, Yang Y, Henein C et al. · The Cochrane database of systematic reviews · 2025 · PMID 40728038
- Clinical trial publication Comparison of topical 0.3% ofloxacin with fortified tobramycin plus cefazolin in the treatment of bacterial keratitisPanda A, Ahuja R, Sastry SS · Eye (London, England) · 1999 · PMID 10707137
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL, in this case via the biomarker or target ABCA1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Ofloxacin approved for Glaucoma?
Ofloxacin has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Glaucoma would be drug repurposing rather than first-in-human development. This does not mean it is approved for Glaucoma. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Ofloxacin in clinical trials for Glaucoma?
ClinicalTrials.gov lists 4 registered trials linking Ofloxacin to Glaucoma: 1 is currently recruiting; 3 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT04200651). The largest enrolment is 4000 participants (NCT03631108). Registration activity spans 2018 to 2020.
What does the evidence show for Ofloxacin in Glaucoma?
Trials of Ofloxacin in Glaucoma are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL, in this case via the biomarker or target ABCA1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.